{{.infobox .infobox-gene}}
| Symbol | SLC22A5 |
| Full Name | Solute Carrier Family 22 Member 5 (OCTN2) |
| Chromosome | 5q31 |
| NCBI Gene ID | 6583 |
| OMIM | 604377 |
| Ensembl ID | ENSG00000197355 |
| UniProt ID | O76076 |
| Associated Diseases | Primary systemic carnitine deficiency, AD, PD |
OCTN2 (SLC22A5), also known as the organic cation/carnitine transporter, is a high-affinity sodium-dependent carnitine transporter that plays a critical role in maintaining cellular energy metabolism throughout the body, particularly in tissues with high fatty acid oxidation demand such as the heart, skeletal muscle, brain, and kidney[@tamai1998]. OCTN2 is encoded by the SLC22A5 gene on chromosome 5q31.1 and belongs to the solute carrier family 22 (SLC22) of polyspecific organic cation transporters.
The transporter was first cloned and characterized in 1998 by Tamai et al., who demonstrated its essential role in maintaining systemic carnitine homeostasis[@tamai1998]. Loss-of-function mutations in SLC22A5 cause primary systemic carnitine deficiency (SCD, OMIM 212140), a potentially fatal autosomal recessive disorder characterized by metabolic crisis, cardiomyopathy, and progressive muscle weakness.
In the central nervous system, OCTN2 is essential for maintaining cerebral carnitine levels, which are critical for energy metabolism, mitochondrial function, and neuroprotection[@kido2001]. The transporter mediates the transport of L-carnitine and acetyl-L-carnitine across the blood-brain barrier, representing a key pathway for delivering these neuroprotective molecules to the brain[@hatanaka2008][@ohtsuki2014].
OCTN2 is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
The SLC22A5 gene spans approximately 32 kb on chromosome 5q31.1 and consists of 11 exons. The gene encodes a 557-amino acid protein with a molecular weight of approximately 63 kDa. The genomic structure is characterized by:
OCTN2 is a member of the major facilitator superfamily (MFS) with 12 transmembrane domains (TMDs) arranged in a characteristic 6+6 topology[@nakanishi1999]. Key structural features include:
| Feature | Location | Function |
|---|---|---|
| N-glycosylation sites | Extracellular loops (Asn58, Asn64) | Protein folding and trafficking |
| PKC phosphorylation sites | Ser/Thr residues in intracellular loops | Regulation of transporter activity |
| PDZ-binding motif | C-terminal (Ser-Ser-Leu) | Protein-protein interactions |
| Na⁺ binding site | Transmembrane domain 1 | Coupling of Na⁺ gradient to carnitine transport |
| Carnitine binding site | Central cavity | Substrate recognition and transport |
The protein localizes to the plasma membrane where it functions as a symporter, coupling the inward transport of carnitine to the influx of Na⁺ ions. The transport is electrogenic, with a stoichiometry of 1:1 (carnitine:Na⁺).
Multiple transcript variants of SLC22A5 have been identified, including:
OCTN2 exhibits high expression in tissues with active fatty acid metabolism:
| Tissue | Expression Level | Primary Function |
|---|---|---|
| Kidney | Very High | Carnitine reabsorption from filtrate |
| Small Intestine | High | Dietary carnitine absorption |
| Heart | Very High | Fatty acid oxidation for energy |
| Skeletal Muscle | High | Muscle energy metabolism |
| Liver | Moderate | Carnitine metabolism and export |
| Testis | Moderate | Energy metabolism for spermatogenesis |
| Placenta | Moderate | Carnitine transport to fetus |
In the brain, OCTN2 is expressed in multiple cell types[@hatanaka2008][@ohtsuki2014]:
Endothelial cells: OCTN2 is highly expressed in brain microvascular endothelial cells forming the blood-brain barrier (BBB), where it mediates the transport of L-carnitine and acetyl-L-carnitine from the peripheral circulation into the brain parenchyma.
Astrocytes: Astrocytes express OCTN2 at high levels, particularly in the end-feet processes that ensheath cerebral blood vessels. OCTN2 in astrocytes is regulated by protein phosphatase PP2A, which directly interacts with the transporter[@wjcikowski2016]. Additionally, tight junction protein ZO-1 controls OCTN2 function in a protein kinase C-dependent manner[@wjcikowski2017].
Neurons: Neuronal expression of OCTN2 has been documented, particularly in cortical and hippocampal neurons, where it contributes to intracellular carnitine accumulation for mitochondrial energy metabolism.
Microglia: Emerging evidence suggests microglial expression of OCTN2, implicating the transporter in neuroinflammatory processes[@cheng2022].
OCTN2 catalyzes the sodium-dependent transport of L-carnitine and acetyl-L-carnitine with high affinity (Km: 1-5 μM)[@tamai1998]. The transport mechanism involves:
Acetyl-L-carnitine (ALCAR), the acetylated form of L-carnitine, is also a high-affinity substrate for OCTN2[@iwanaga2023]. This is particularly relevant for brain function because:
OCTN2 activity and expression are regulated by multiple mechanisms:
Transcriptional regulation:
Post-translational regulation:
Trafficking regulation:
Mutations in SLC22A5 cause primary systemic carnitine deficiency (SCD, OMIM 212140), an autosomal recessive disorder with an estimated incidence of 1 in 40,000-120,000 live births. The disease is characterized by:
Treatment with high-dose L-carnitine supplementation is effective in preventing metabolic crises and improving cardiac function in most patients.
OCTN2 dysfunction has been implicated in Alzheimer's disease pathogenesis through multiple mechanisms[@wang2020][@katare2022]:
Energy metabolism impairment: The brain relies heavily on oxidative metabolism, and carnitine is essential for fatty acid oxidation in mitochondria. Impaired OCTN2 function may reduce cerebral carnitine levels, contributing to mitochondrial dysfunction—a hallmark of AD.
Mitochondrial dysfunction: Carnitine is required for the transport of fatty acids into mitochondria for β-oxidation. OCTN2 dysfunction may lead to impaired mitochondrial energy production in neurons, making them vulnerable to metabolic stress.
Acetyl-L-carnitine deficiency: ALCAR has been shown to have neuroprotective effects in AD models, including improving mitochondrial function, reducing amyloid toxicity, and enhancing cognitive performance[@leoni2022]. Impaired OCTN2 function may reduce ALCAR delivery to the brain.
Neuroinflammation: Carnitine has anti-inflammatory properties, and OCTN2 dysfunction may exacerbate neuroinflammatory processes in AD[@cheng2022].
Amyloid interaction: Some studies suggest that Aβ may interact with carnitine transport systems, potentially altering OCTN2 function.
OCTN2 and carnitine metabolism are relevant to PD through several mechanisms[@yang2021][@ferrara2021]:
Mitochondrial dysfunction: PD is characterized by mitochondrial complex I deficiency. Carnitine supplementation has been shown to protect against mitochondrial dysfunction and dopaminergic neuron loss in experimental models.
Oxidative stress: Dopaminergic neurons are particularly vulnerable to oxidative stress. Carnitine has antioxidant properties and may protect against oxidative damage.
Energy metabolism: The substantia nigra has high energy demands. Impaired carnitine transport via OCTN2 may compromise neuronal energy metabolism.
Neuroinflammation: Carnitine has immunomodulatory properties that may benefit PD pathology.
Over 100 pathogenic variants in SLC22A5 have been identified in patients with primary systemic carnitine deficiency, including:
| Variant Type | Examples | Effect |
|---|---|---|
| Missense | p.R169Q, p.P269L, p.R483H | Reduced transporter function |
| Nonsense | p.R288*, p.W398* | Truncated non-functional protein |
| Frameshift | c.505_506del, c.844_845insG | Altered protein sequence |
| Splice site | c.1018-1G>A, c.1476+1G>T | Aberrant mRNA processing |
| Large deletion | Exon 5-7 deletion | Partial protein loss |
Common polymorphisms in SLC22A5 may affect transporter function[@zhao2023]:
OCTN2 polymorphisms can affect drug response:
Targeting OCTN2 has therapeutic potential in several contexts:
Neurodegenerative diseases: L-carnitine and acetyl-L-carnitine supplementation have shown promise in AD and PD models, with ongoing clinical trials evaluating their efficacy.
Drug delivery: OCTN2 can be exploited for brain drug delivery using carnitine-conjugated nanoparticles[@geldenhuys2018]. This strategy leverages OCTN2-mediated transport to enhance drug penetration across the BBB.
Metabolic disorders: OCTN2 modulators may be useful in treating metabolic syndrome and fatty liver disease.
OCTN2 can transport various pharmaceuticals:
| Drug Class | Examples | Interaction |
|---|---|---|
| Antidiabetic | Metformin | Competition for transport |
| Antiviral | Valacyclovir | OCTN2-mediated uptake |
| Anticonvulsant | Gabapentin | Potential transport |
| Histamine H2 blocker | Cimetidine | Inhibitor of transport |
Inhibitors:
Activators:
OCTN2 interacts with several proteins:
OCTN2 functions alongside other organic cation transporters:
[@kido2001]: Kido et al. Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. Biol Pharm Bull. 2001;24(4):365-370.
[@hatanaka2008]: Hatanaka et al. Localization of organic cation/carnitine transporter (OCTN2) in cells forming the blood-brain barrier. Brain Res. 2008;1228:170-176.
[@ohtsuki2014]: Ohtsuki et al. Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model. J Pharm Sci. 2014;103(12):3965-3972.
[@wjcikowski2016]: Wójcikowski et al. Protein phosphatase PP2A - a novel interacting partner of carnitine transporter OCTN2 (SLC22A5) in rat astrocytes. J Neurochem. 2016;138(1):93-101.
[@wjcikowski2017]: Wójcikowski et al. Tight junction protein ZO-1 controls organic cation/carnitine transporter OCTN2 (SLC22A5) in a protein kinase C-dependent way. Mol Neurobiol. 2017;54(3):1743-1754.
[@geldenhuys2018]: Geldenhuys et al. L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2. Oncotarget. 2018;9(33):23044-23058.
[@tamai1998]: Tamai et al. Molecular cloning and functional expression of a novel carnitine transporter from human kidney. Biochim Biophys Acta. 1998;1414(1-2):125-134.
[@nakanishi1999]: Nakanishi et al. Expression of organic cation/carnitine transporter (OCTN2) in mouse small intestine. Pharm Res. 1999;16(10):1616-1621.
[@katare2022]: Katare et al. Carnitine and cognitive decline: insights from Alzheimer's disease research. Ageing Res Rev. 2022;73:101534.
[@yang2021]: Yang et al. L-carnitine protects against mitochondrial dysfunction and dopaminergic neuron loss in Parkinson's disease models. Free Radic Biol Med. 2021;174:87-99.
[@iwanaga2023]: Iwanaga et al. OCTN2-mediated transport of acetyl-L-carnitine in neurons and astrocytes. J Neurochem. 2023;165(3):456-471.
[@wang2020]: Wang et al. Carnitine deficiency and metabolic dysfunction in Alzheimer's disease. J Alzheimers Dis. 2020;77(3):1261-1275.
[@cheng2022]: Cheng et al. Role of OCTN2 in neuroinflammation and microglial activation. Glia. 2022;70(7):1341-1358.
[@moretti2021]: Moretti et al. Carnitine metabolism in aging: implications for brain energy metabolism. Mech Ageing Dev. 2021;194:111425.
[@zhao2023]: Zhao et al. OCTN2 genetic variants and risk of neurodegenerative diseases. Neurobiol Aging. 2023;125:88-97.
[@leoni2022]: Leoni et al. Acetyl-L-carnitine and cognitive function: therapeutic potential in Alzheimer's disease. CNS Drugs. 2022;36(4):319-334.
[@ferrara2021]: Ferrara et al. Carnitine and mitochondrial function in Parkinson's disease. Mov Disord. 2021;36(9):2062-2075.